DNminer Launches Cloud Mining Services for Bitcoin and XRP Enthusiasts
DNminer Logo
LOS ANGELES, May 19, 2025 (GLOBE NEWSWIRE) -- DNminer, a digital platform specializing in cryptocurrency mining, announces the launch of its cloud mining services designed for Bitcoin and XRP mining. The platform provides an easy, secure, and affordable way for individuals to participate in mining without the need for owning or maintaining physical mining equipment.
As the demand for cryptocurrencies grows, many individuals are seeking ways to be part of the mining economy without the technical and financial burden of setting up their own rigs. DNminer responds to this need by offering cloud mining services that allow users to lease computing power from remote data centers. This approach significantly lowers the entry barrier, enabling anyone with an internet connection to begin earning cryptocurrency.
'Our goal is to introduce a practical and user-friendly platform for mining popular digital currencies like Bitcoin and XRP,' said a spokesperson for DNminer. 'With flexible packages and real-time performance tracking, we want to empower users to start mining with confidence.'
DNminer's cloud mining solution offers several plans to accommodate different budgets and mining goals. Users can select the desired contract and duration, with no need for hardware maintenance, electricity costs, or cooling infrastructure. Once subscribed, the mining process starts automatically, and users can monitor their earnings through a streamlined dashboard interface.
The platform currently supports cloud mining for Bitcoin and XRP, two of the most recognized digital currencies in the world. With data centers powered by high-performance mining hardware and enhanced security protocols, DNminer aims to provide stable performance and uptime.
Security and transparency are central to DNminer's operations. All mining statistics, payouts, and performance reports are easily accessible within the user account. The platform also provides customer support to assist with any inquiries related to accounts or mining contracts.
Understand the potential returns for different investment contract durations.
Whether users are crypto beginners or seasoned investors looking to diversify their portfolio, DNminer presents a scalable and hassle-free solution to engage in cloud mining.
To learn more or begin mining today, visit https://dnminer.com.
About DNminer
DNminer is a cryptocurrency cloud mining platform offering secure and flexible solutions for users interested in Bitcoin and XRP mining. The platform focuses on accessibility, transparency, and delivering mining services without technical complexity.
Media Contact:
Tomlin
DNMiner
+44 7349100987
[email protected]
https://dnminer.com/
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/98febd88-449a-4410-a968-ab3cf5409fe4
https://www.globenewswire.com/NewsRoom/AttachmentNg/46375c2c-363b-4b9b-9fbc-3f38b8866c7d
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 minutes ago
- Associated Press
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ('Silo' or the 'Company'), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. 'The addition of Bitcoin to our treasury holdings is a strategic decision aimed at diversifying our assets to include a digital store of value with what we believe has significant upside potential,' said Eric Weisblum, CEO of Silo. 'Our purchase of Bitcoin is intended to provide a safeguard against inflation and is expected to position Silo to preserve and optimize long-term shareholder value.' About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. Forward-Looking Statements This news release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words 'could', 'believe', 'anticipate', 'intend', 'estimate', 'expect', 'may', 'continue', 'predict', 'potential', and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ('Silo' or 'the Company') to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law. Contact 800-705-0120 [email protected]
Yahoo
38 minutes ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
LED Lighting, EV Charging Station and Electrical Maintenance Solutions Provider Orion Hosts Q4 Conference Call Thursday, June 26th at 10am ET
MANITOWOC, Wis., June 05, 2025 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electrical vehicle charging station, and maintenance services solutions, will host a conference call and webcast to review its fourth quarter and fiscal 2025 results on Thursday, June 26, 2025 at 10:00 a.m. ET. Orion will release results prior to the market's opening that day. Webcast and Call Details Date / Time: Thursday, June 26th at 10:00 a.m. ET Live Call Registration: call participants must pre-register using the URL above to receive the dial-in information. You may re-register if you lose the dial-in or PIN #. Webcast & Replay: About Orion Energy Systems (at provides energy efficient LED lighting and controls, electrical vehicle (EV) charging solutions, and electrical maintenance services. Orion specializes in turnkey design-through-installation solutions for large national customers as well as projects through ESCO and distribution partners. Orion is committed to helping customers achieve their business, financial and environmental goals with high quality, innovative and safe solutions delivered with high levels of customer service and reliability. Orion is committed to operating responsibly throughout all areas of our organization. Learn more about our Sustainability and Governance priorities, goals and progress here or visit our website at Engage with UsX: @OrionLighting and @OrionLightingIRStockTwits: @OESX_IR Investor Relations Contacts Per Brodin, CFO William Jones; David Collins Orion Energy Systems, Inc. Catalyst IR pbrodin@ (212) 924-9800 or OESX@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
